Vivus VVUS

  1. All
  2. Commentary
  3. Headlines
    1. Orexigen Launches Contrave - Watch For Traction

      Headlines

      Mon, 20 Oct 2014

      Orexigen Launches Contrave - Watch For Traction

    2. Are People Too Concerned About Orexigen's Contrave Label?

      Headlines

      Sun, 19 Oct 2014

      over 10 years. This is following the approval of Belviq (Arena Pharmaceuticals (NASDAQ: ARNA )) and Qsymia ( Vivus (NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has tanked, dropping nearly 35% from its pre-approval

    3. What To Watch For As Orexigen's Launch Approaches

      Headlines

      Thu, 16 Oct 2014

      denying that Wall Street will be there as well. When launched, Orexigen will join Arena (NASDAQ: ARNA ) and Vivus (NASDAQ: VVUS ) as one of three companies with FDA approved anti-obesity drugs on the market. Other players looking to enter

    4. Orexigen On A Tear - In The Wrong Direction

      Headlines

      Tue, 7 Oct 2014

      potential market to tap into. The real story is that all of the hype and potential of the market size fizzled when Vivus (NASDAQ: VVUS ) launched Qsymia and Arena (NASDAQ: ARNA ) launched Belviq. It was not long after the launch of these drugs

    5. Vivus announces journal publication of Qsymia study results in type 2 diabetes

      Headlines

      Mon, 6 Oct 2014

      A paper examining the results from two studies of Vivus ' (NASDAQ: VVUS ) Qsymia (phentermine and topiramate extended-release) plus lifestyle modification in overweight/obese patients with type

    6. A Look At Arena's Other Drug

      Headlines

      Fri, 3 Oct 2014

      anti-obesity drugs that were being developed simultaneously. Prior to the approval of Arena's Belviq and Vivus Inc.'s (NASDAQ: VVUS ) Qsymia, the FDA had not approved any anti-obesity drug for nearly a decade. The excitement over the

    7. Premature Combination Use Of Belviq And Phentermine Is A Risk

      Headlines

      Sun, 28 Sep 2014

      By Rx Stocks : Obesity drugs, historically, have had poor market success and notable safety issues. Meridia [ Sibutramine ] was withdrawn from the market by Abbott (NYSE: ABT ) because it was associated with an increase in major adverse cardiovascular events [MACE] in the SCOUT trial. The market ...

    8. Belviq Sales Benefit From Advertising - Up 2.8%

      Headlines

      Fri, 26 Sep 2014

      bigger numbers than this), it is positive in that the season is what it is, and the competitor, Qsymia from Vivus (NASDAQ: VVUS ), saw scripts decline by almost 1%. Posting week over week gains at this stage, even if more modest than we

    9. Vivus Up On Erectile Dysfunction Drug - What Should Investors Expect?

      Headlines

      Fri, 19 Sep 2014

      By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced today that the company ..... hour or longer to bring results. Vivus stock soared as high as $4.82 during ..... there. As stated, the label gives Vivus a leg up on the competition in the

    10. It Takes Less Than 15 Minutes To Buy VVUS Shares!

      Headlines

      Fri, 19 Sep 2014

      International (NASDAQ: ENDP ). Vivus Pharmaceuticals (NASDAQ: VVUS ) shares have fallen dramatically ..... What is the revenue potential for VIVUS ? There has been, at times wild ..... Discussion of the earnings potential Vivus ' Complete Story »

    « Prev12345Next »
    Content Partners